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Abstract
Hepatitis C virus (HCV) infection is a major worldwide problem causes acute and chronic HCV infection. Current
treatment of HCV includes pegylated interferon-a (PEG IFN- a) plus ribavirin (RBV) which has significant side effects
depending upon the type of genotype. Currently, there is a need to develop antiviral agents, both from synthetic
chemistry and Herbal sources. In the last decade, various novel HCV replication, helicase and entry inhibitors have
been synthesized and some of which have been entered in different phases of clinical trials. Successful results have
been acquired by executing combinational therapy of compounds with standard regime in different HCV replicons.
Even though, diverse groups of compounds have been described as antiviral targets against HCV via Specifically
Targeted Antiviral Therapy for hepatitis C (STAT-C) approach (in which compounds are designed to directly block
HCV or host proteins concerned in HCV replication), still there is a need to improve the properties of existing
antiviral compounds. In this review, we sum up potent antiviral compounds against entry, unwinding and
replication of HCV and discussed their activity in combination with standard therapy. Conclusively, further
innovative research on chemical compounds will lead to consistent standard therapy with fewer side effects.
Introduction
H C Vb e l o n g i n gt ot h ef a m i l yF l a v i v i r i d a es i g n i f i e st ob e
an entire global dilemma which parades the variability
of genome translated into six genotypes and more than
80 subtypes. HCV has infected 200 million people
worldwide [1], of which 10 million individuals (6% of
the population) have been spotted in Pakistan [2]. HCV
was firstly recognized in 1989 [3], comprising of 9.6 kb
positive sense genome. It encodes a single polyprotein
precursor of 3010 amino acids having an internal ribo-
some entry site at 5’ untranslated region (UTR), vital for
the translation. This polyprotein precursor is co-transla-
tionally processed by cellular and viral proteases into
three structural proteins (core, E1 & E2) and seven non-
structural proteins (P7, NS2, NS3, NS4A, NS4B, NS5A
& NS5B) [4] (Figure 1).
HCV infection is generally going to be clinically
imperceptible after 3-12 weeks of incubation [5].
Currently, it is estimated that 50-80% of patients have
successively infected with chronic infection and 2-5%
have developed hepatocellular carcinoma per annum.
HCV has the capacity to stimulate immunopathological
effects, engendering reactive oxygen species (ROS)
impend indirectly fibrogenetic effects [6] leading to
steatosis and cirrhosis [7]. HCV infection commences
while interaction of virions instigate with various cellular
receptors [8]. After internalization of virions by clathrin-
mediated endocytosis [9,10], HCV RNA is being
released into cytosol followed by translation and pro-
gression to viral proteins. A large number of viral pro-
geny particles are released through the secretory
pathway after assemblage of new genomic RNA and
structural proteins.
Recently, there is no precise antiviral regime for the
deterrence of HCV infection. Nevertheless, current stan-
dard treatment pegylated interferon-a (PEG IFN- a)i n
combination with ribavirin (RBV) have been employed
with certain side effects and slow response rate espe-
cially in patients infected with HCV genotype 1a and1b
[11,12]. Now a day, various novel antiviral inhibitors
have been accounted showing a promising approach
against HCV.
Antiviral Drugs & Their Mode of Action
Mainly, an array of attempts has been focused especially
on these targets: NS3-4A serine protease, RNA helicase
activity of NS3, NS5B RNA-dependent RNA polymerase
(RdRp), agents that enhance immunomodulatory activity
by developing HCV replicon system. Likewise, the HCV
replicon system illustrated an exclusive drug-screening
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to hamper the viral enzymes and HCV RNA replication
process in cellular environment. However, antiviral com-
pound-resistant mutations are credibly arising in viral
genome due to high heterogeneity while developing the
specific HCV protease and polymerase inhibitors [13].
Various efforts are being made in screening antiviral
compounds against different HCV replicon systems
[14-16].
Inhibitors of HCV RNA Replication
HCV replication is instigated by the formation of repli-
case complex which is allied with intracellular mem-
brane containing cellular proteins. Replicase complex
consists of cleavage products of HCV polyprotein pre-
cursor especially NS3-5B which play an important role
in replication. Along with these proteins and cis acting
RNA elements, various host factors are also involved in
HCV RNA replication [17-19]. NS5B is the RNA-depen-
dent RNA polymerase (RdRp) which can start RNA
synthesis de novo. RdRp activity is shown to be
enhanced by interacting with cyclophilin B and viral fac-
tors such as NS3 and NS5A. A negative-strand copy of
viral genome is primarily produced by NS5B RdRp. In-
vitro this enzyme has a preference for primer-dependent
RNA synthesis, either by elongation of a primer hybri-
dized to an RNA homopolymer or through a copy-back
mechanism while exploiting heteropolymeric templates
[20,21]. NS3 protein possesses helicase, protease and
RNA triphosphatase activity. Even though NS3 exhibits
innate proteolytic activity, NS4A cofactor is required for
the cleavage of polyprotein. Due to vague understanding
of helicase enzymology, NS3 helicase is a hard-hitting
target for drug designing [22].
The illustration of HCV replication is made possible
by the development of HCV cell culture system. First
HCV replicon was generated in human hepatome cell
line (Huh-7) having genotype 1b subgenomic RNA
along with 5’ UTR, neomycin phosphotransferase gene
(NPT), internal ribosome entry site (IRES) of encephylo-
myocarditis virus (EMCV)-HCV NS3-4A-4B-5A-5B-
HCV 3’ UTR. RNA replication, virus-host relations,
screening of antiviral drugs and their mechanism are
best studied by the replicon system [23]. Nucleosides
inhibitors (NI) as well as non nucleoside inhibitors
(NNI) of HCV NS5B RdRp have been appraised. Specifi-
cally Targeted Antiviral Therapy for hepatitis C (STAT-
C) approach is now being currently used to develop
drugs that basically target specific enzymes involved in
HCV replication. STAT-C drugs such as polymerase
and protease inhibitors are presently accessible only in
different phases of clinical trials.
Debio 025, a non-immunosuppressive cyclosporine
(Cs) analogue, is found to exhibit novel inhibition of
HCV replication when used alone or in combination
with STAT-C inhibitors. To date, Debio 025 was pooled
with RBV, VX-950 a protease inhibitor, 2’-C-Methylcyti-
dine (2’-C-MeCyt) a NI and JT-16 a NNI. All these
amalgamations produced additive antiviral effects show-
ing the lack of interference with biological activity of
each other which may either, resulted in synergistic or
antagonistic effect. Combinations of low dose of Debio
025 with specific STAT-C inhibitors also prevent the
progress of STAT-C inhibitor-resistant variant; hence, it
Figure 1 HCV structure : HCV enclosing a single stranded RNA of 9.6 kb. The genome carries a single long open reading frame (ORF) which on
processing forms a polyprotein that is proteolytically cleaved into distinctive products. The HCV polyprotein is cleaved co- and post-
translationally by cellular and viral proteinases into 10 different products, with the structural proteins located in the amino- terminal one-third
and the nonstructural (NS) replicative proteins in the rest. (5)
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ment of HCV infection [24]. In phase II study of clinical
trials, it is being found that Debio 025 is a novel HCV
inhibitor by binding to cyclophilin A (CyP) in domain II
of NS5A which is crucial for replication. Resistance out-
line of Debio 025 presents a distinctive selection in
treating chronic HCV infection, both as the backbone of
forthcoming combination therapy with other com-
pounds for treatment and as save therapy for patients
anchoraging resistance mutations to other anti-HCV
agents [25].
Combined effect of HCV-796 (an NNI of HCV NS5B)
and boceprevir SCH 503034 (an inhibitor of NS3 serine
protease) was tested to check their competence for pro-
ducing resistant replicon variants. Conclusively, substan-
tial antiviral efficiency was assessed in combinational
treatment along with low emergence rate of viral var-
iants with reduced propensity. This study offers a basis
for the clinical estimation of three-part combination of
PEG IFN-a, boceprevir and HCV-796 [26].
Since RdRp is deficient in proof reading activity dur-
ing replication so error rate is very high, resulting in an
ample genetic diversity in viral populace within each
patient. This diversification in genome is directly related
with the low response to HCV RdRp inhibitors espe-
cially in patients of genotype 1a and 1b [27,28].
PF-00868554, an NNI of HCV RdRp, has demon-
strated both specificity and capability for 1a and 1b gen-
otypes including clinical and laboratory isolates. During
in-vitro resistance study of PF-00868554, amino acid
(AA) changes were recognized at the allosteric site of
the polymerase, comprising M423T/V/I, M426T, and
I482T, but switching at M423 resulted in relatively
much resistance than others. Notably, replicons enclos-
ing these resistance changes have found no cross-resis-
tance with IFN and other polymerase inhibitors,
sustaining the make use of PF-00868554 in combination
therapies [29].
Antiviral activity of 7-deazaneplanocin A (7-DNPA) is
reported against HCV with low cell toxicity in HCV
RNA replicon system in Huh-7 cell line. Anti-HCV
activity of 7-DNPA is comparable to the 2’-C-Me-cyto-
sine (2’-C-Me- C) or 2’-F-C-Me-cytosine (2’-F-C-Me-C)
which were used as positive controls, by quantifying
through real time RT-PCR. Various derivatives of 7-
DNPA are synthesized by replacing different functional
groups at 7-position of DNPA, of which some are
devoid of anti-HCV activity while others such as 7-car-
boxamide derivative exhibiting significant antiviral activ-
ity against HCV [30].
Combinations of nucleoside analogues b-D-2’-C-
methylcytidine (2’-C-MeC; NM-107) or b-D-2’-deoxy-2’-
fluoro-2’- C-methylcytidine (2’-F-C-MeC; PSI-6130) with
interferon-a 2b (IFN-a2b) plus ribavirin (RBV) were
assessed in subgenomic HCV relicon. b-D-2’-C-methyl-
cytidine (2’-C-MeC; NM-107) was the first nucleoside
HCV inhibitor. Triple combination of valopicitabine
(NM-283), the 3’-valine ester of b-D-2’-C-methylcytidine
(2’-C-MeC; NM-107) along with IFN and RBV resulted
in 70% decline in viral load, but NM-283 was interdicted
due to gastrointestinal side effects [31]. The distinction
of combination index (CI) of two sets of three combina-
tions pointed towards striking synergism of NM-107
with IFN + RBV than PSI-6130 combination to inhibit
HCV RNA replication [31].
Nitazoxanide (NTZ) was originally ascertained for
intestinal protozoan infection; later on its antiviral char-
acteristics were established. NTZ, and its metabolite,
tizoxanide (TIZ), exhibit constancy with resistance in
HCV replicon containing cell line bestowed by the
changes in the host, not by mutagenesis in virus. Inhibi-
tion of HCV RNA replication was observed by subject-
ing HCV replicon containing cell line to G418 and
different concentrations of compound [32]. High SVR
rate of nitazoxanide along with interferon suggested that
nitazoxanide can be exercised instead of ribavirin to
avoid side effect of this drug.
Another newly discovered antiviral compound, clemi-
zole, is found to exhibit influential antiviral activity
against NS4B RNA binding and HCV replication by
using luciferase reporter-linked HCV replication assay.
Clemizole has succumbed high synergistic effects with
various protease (VX950 & SCH503034) and additive
effects with polymerase inhibitors (NM283 & HCV796).
Furthermore, the clemizole-SCH503034 combination
reduces the manifestation of resistance exclusive of
bestowing cross-resistance [33].
Cyclosporine A (CsA), an immunosuppressant for
transplanted patients, has currently come forward as a
forthcoming antiviral compound against HCV. It is eval-
uated that CsA persuasively inhibits HCV replication by
illustrating the various HCV derived replicons with vari-
able levels of CsA resistance due to mutations in NS5B.
Transformed HCV replicons integrated with these muta-
tions proved the resistance to CsA. Increased ability of
mutant NS5B is associated with the enhanced binding
to RNA in the presence of CsA and intramolecular
interactions between the residues of thumb and C-term-
inal domains are crucial for HCV replicase function
[34].
An innovative compound, ACH-806 (GS 9132) is
characterized as antiviral agent against HCV by using
HCV replicon system. ACH-806 was discovered by
using HCV replicon cells [35]. Mechanism of action stu-
dies have exposed that ACH-806 averts the apposite
pattern of replication complexes by sharply binding to
NS4A [35]. Moreover, ACH-806 has been inveterated to
decelerate HCV replication in genotype 1 HCV infected
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city prohibits its additional clinical progress [36].
25-hydroxychloesterol (25-HC) has been ascertained
as anti-HCV agent by modifying the mevalonate path-
way [37]. Transcriptional profiling of 25-HC was exe-
cuted on Huh-7 cells containing HCV replicons.
V a r i o u ss e t so fg e n e sw e r eu p -a n dd o w nr e g u l a t e d
involved in the mevalonate pathway and instituted tran-
scriptional changes resulting in the inhibition of HCV
replication. The identified genes which may act as HCV
markers are indirectly involved in the inhibition of HCV
replication [38].
A class of anionic tetraphenylporphyrins is identified
as explicit inhibitors of HCV replicons. Meso-tetrakis-(3,
5-dicarboxy-4,4’-biphenyl) porphyrin is found to display
in-vitro antiviral activity against HCV genotype 1b repli-
cons by targeting viral replicase but less proficient
against the genotype 2a (JFH-1) replicon. Synergistic
studies have shown that the combination of Meso-tetra-
kis-(3, 5-dicarboxy-4,4’-biphenyl) porphyrin with BILN
2061 and with IFN-a was additive to synergistic which
lead to almost 90% inhibition of HCV replication [39].
TMC435350 is found to be a novel and specific pro-
tease inhibitor by establishing preclinical models and in
vitro assays. TMC435350 is a potent HCV NS3/4A ser-
ine protease inhibitor which displays synergistic effects
in combination with IFN-a and additive effects with
RBV. Additionally, NS5B inhibitors NM-107 and HCV-
796 in combination with TMC435350 showed synergism
which debates the effectiveness of TMC435350 clinical
antiviral therapy against HCV [40].
SCY-635 is a potent non-immunosuppressive disubsti-
tuted analogue of CsA showing evidence of antiviral
activity against HCV by operating at host CyP, which is
imperative for HCV RNA replication. SCY-635 stalled
the peptidyl prolyl isomerase activity of CyP at nanomo-
lar concentrations by testing in HCV replicon cell line.
Further clinical trials of SCY-635 may prove to be bene-
ficial in drug development for HCV in future [41].
Safety and pharmacokinetics of SCY-635 have also been
studied in chronically HCV infected patients [42].
By doing in-vitro resistance study of AG-021541, it is
being demonstrated that AG-021541 is a novel dihydro-
pyrone NNI of HCV replication. AG-021541 marks to
hit HCV RNA polymerase at the thumb-base allosteric
site. As resistance changes due to AG-021541 remained
entirely susceptible to IFN and polymerase inhibitors
targeting sections distinct from the AG-021541 binding
site. Due to lack of cross resistance, combinational ther-
apy of AG-021541 with other polymerase or nonpoly-
merase inhibitors would be significantly accommodating
in future [43].
ITMN-191 (R7227) is a peptidomimetic inhibitor of
NS3/4A protease of HCV. ITMN-191 introverted a
reference genotype 1 NS3/4A protein in a time-
dependent manner, which is a characteristic of an inhi-
bitor with a two-step binding mechanism and a low
dissociation rate. Under pre-equilibrium circumstances,
small quantity of ITMN-191 half-maximally inhibited
the reference NS3/4A protease, but a 35,000-fold-
higher concentration did not substantially restrain a
group of 79 proteases, ion channels and transporters.
Combinational therapeutic regime of ITMN-191
(R7227) is considered to be helpful in curing chronic
hepatitis C [44].
GS-327073, 5-[{3-(4-chlorophenyl)-5-isoxazolyl}
methyl]-2-(2, 3-difluorophenyl)-5H-imidazo [4,5-c] pyri-
dine is proved to be highly effective against HCV repli-
cation by assessing in various HCV subgenomic
replicons (genotypes 1b, 1a and 2a), in JFH-1 infectious
system and against replicons which are sustained to be
resistant for various HCV inhibitors. GS-327073, reveal-
ing pharmacokinetic characteristics in-vitro has main-
tained anti-HCV activity for resistant replicons [45].
P3 aza-peptide analogue (exhibiting anti HCV activity)
of a novel HCV protease blocker (BILN 2061) has been
synthesized. Anti HCV activity of newly synthesized
derivative is shown to be less effective than the parent
compound in HCV sub-genomic replicon assay. Config-
uration at P3 has interrupted the H-bond conformation
which is necessary for the binding of compound to
active site of HCV NS3 protease [46]. A series of gem-
dialkyl naphthalenones have shown to exhibit antiviral
activity against HCV. The extent of efficient inhibition
activity is correlated with the length of carbon chain.
Gem-dialkyl naphthalenone derivatives are found to be
novel HCV polymerase inhibitors. By performing the
modifications at carbon-1 of B ring, thriving results
against HCV polymerase were attained in HCV sub-
genomic replicons [47].
Novel sulfonamide P4-capped ketoamide second gen-
eration inhibitors of hepatitis C virus NS3 serine pro-
tease have been discovered. Discovery of one of them,
showing potent anti HCV activity, is contributed by
introducing the sulphonamide moiety and optimization
of P1 residue. This potent inhibitor of HCV subgenomic
replication reveals improved cellular potencies and good
oral exposure in rat, dogs and monkey [48].
Telaprevir in combination with standard antiviral ther-
apy against HCV bestowed rapid viral response and con-
siderably declined the HCV RNA levels. Further,
extensive studies are conducted to assess sustained viro-
logical response while administration of combinational
therapy [49]. Telaprevir is the first drug against HCV
presently in progress which exclusively blocks HCV
NS3/4A serine protease.
A new series of geldanamycin (GA) derivatives have
been synthesized which were evaluated as antiviral
Rehman et al. Genetic Vaccines and Therapy 2011, 9:11
http://www.gvt-journal.com/content/9/1/11
Page 4 of 10compounds against HCV in GS4.3 HCV replicon cells.
Many of these synthesized compounds exhibited compe-
titive anti-HCV activity [50].
Various other novel HCV NS5B polymerase inhibitors
have recently been discovered such as pyrano [3,4-b]
indole based inhibitors, tricyclic 5,6-dihydro-1H-pyridin-
2-ones, benzothiadiazine and 1,4-benzothiazine, 4-(1
/,1
/
dioxo-1
/dihydro-1
/l
6-benzo [1
/,2
/,4
/] thiadiazin-3
/-yl)-5-
hydroxy-2H-pyridazin-3-ones, Pyrrolo [1,2-b] pyridazin-
2-ones, 2-(1,1-dioxo-2H-[1,2,4] benzothiadiazin-3-yl)-1-
hydroxynaphthalene derivatives, pyrano [3,4-b] indole.
(Structures are cited in figure 2).
Helicase Inhibitors
NS3 helicase plays an important role in unwinding of
double-strand DNA and duplex RNA. DEAD box pro-
teins belong to helicase superfamily 2 that facilitate
mRNA splicing, mRNA export, translation, protein pro-
cessing, RNA packaging into virions, mitochondrial gene
expression and probably aid RNA-dependent RNA repli-
cation [51-54]. DEAD-box stands for exceedingly con-
served motif comprised of Asp-Glu-Ala-Asp. The two
most striking targets on NS3 helicase are ATP and RNA
binding sites while other distinctive facets may be uti-
lized as target for drug development [55]. From a biolo-
gical point of view, activities of protease and helicase
co-exist in-vivo,t h u sm a yp r o v et ob eau s e f u la n t i v i r a l
target against HCV. Helicase and polymerase form viral
helicase multi-protein complex. So, it is essential to
inhibit functions that are fundamental for helicase
activity.
Helicase inhibitors may act in different mechanisms
such as by inhibiting NTPase activity, RNA binding and
NTP hydrolysis coupling at the unwinding reaction.
A new series of compounds, acridone derivatives, were
tested to measure inhibitory effects of derivatives against
NS3 helicase activity of HCV in sub-genomic replicon
assay. These substituted compounds were also investi-
gated for transcription inhibition in-vitro based on the
DNA-dependent T7 RNA polymerase. The majority of
compounds were displayed as transcription inhibitors.
Two compounds, N-(pyridin-4-yl)-amide and N-(pyri-
din-2-yl)-amide of acridone-4-carboxylic acid are com-
petent RNA replication inhibitors verifying that the
acridone derivatives may be deemed as impending anti-
viral mediator [56].
 
Debio 025                                 HCV-796                                       Boceprevir                                         PF-00868554                7-DNPA                      
TIZ                             NTZ                          Clemizole                           25-HC             P3 aza-peptide analogue                                                              
 
                                     P4-capped ketoamide 
 
 
 
 
 
AG-021541                   Anionic tetraphenylporphyrin         Telaprevir                                             ACH-806                       GS-327073                        
 
SCY-635                Cyclosporine A              ITMN-191                    TMC-435350                      NM-107         PSI-6130            NM-283                      
Figure 2 Inhibitors of HCV replication.
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benzimidazol-2-yl) phenyl] benzene-1, 4-dicarboxamide
((BIP)2 B) is established to inhibit capability of HCV
helicase to split double stranded DNA and RNA. (BIP)
2B inhibited helicase-catalyzed ATP hydrolysis in the
presence of RNA transitional concentrations, signifying
RNA and (BIP)2B contend for alike binding site [55].
Helicase assay was performed to screen inhibitors by
utilizing DOCK program. Fragment-based explorations
were exploited to recognize triphenylmethane derivatives
for other persuasive inhibitors. 3-bromo-4-hydroxyl sub-
stituted derivative masked HCV replication in the HCV
replicon cells. For that reason, this inhibitor with struc-
tural novelty may act as a functional gibbet for the
sighting of innovative HCV NS3 helicase inhibitors [57].
The most persuasive benzotriazole helicase inhibitors
were recognized throughout the duration of random
screening study [58,59]. In particular, 4, 5, 6, 7- tetrabro-
mobenzotriazole (TBBT) acknowledged as a powerful and
exceedingly discriminating inhibitor of protein kinase 2,
which displayed inhibitory concentration (IC50) values of
20 μM and 5,6-dichloro-1-(b-D-ribofuranosyl) benzotria-
zole (DRBT) demonstrated IC50 values of 1.5 μM.
The most active chemical entity, 3, 5, 7-tri [(40-methyl-
piperazin-10-yl) methyl] tropolone inhibited RNA repli-
cation by 50% at an effective concentration (EC50) of 46.9
μM, while the most competent one was 3, 5, 7-tri [(30-
methylpiperidin-10-yl) methyl] tropolone having EC50 of
35.6 μM. These derivatives are the first helicase inhibitors
that block replication of HCV with the capability of caus-
ing the emergence of resistant mutants [60].
Another HCV helicase inhibitor, QU663, illustrated
discriminating inhibition without disturbing NS3 heli-
case hydrolysis potential. QU663 might function as a
potent inhibitor with respect to nucleic acid substrate
by lessening the likeness of the enzyme for the sub-
strate. QU663 blocks NS3 unwinding activity, thus mak-
ing it a potential competitor for antiviral drugs against
HCV [61].
Two series of compounds exhibiting aminophenylben-
zimidazole and benzimidazole like entities are patented
by ViroPharma Inc. as HCV helicase inhibitors [62].
Vertex Pharmaceuticals Inc. accounted various ami-
nothiadiazoliums which also exhibit anti-helicase activity
but with lower efficacy [63]. Two derivatives of 2-aryl-
benzofuran isolated from Mori cortex radicis have
shown potent inhibition against HCV NS3 helicase [62].
(Structures are cited in figure 3).
Inhibitors of HCV Entry
For the development of antiviral drugs against HCV
entry, enveloped proteins have been extensively
utilized, especially targeting the carbohydrate moieties
on E1 and E2 proteins. The first step of HCV life cycle
involves the attachment of viral particles to the cell
surface which is followed by internalization. So, various
entry inhibitors are reported to prevent the entry of
virions.
PD 404, 182, primarily a bacterial KDO 8-P synthase
inhibitor, has revealed the restraining of HCV pseudo-
particles (HCVpp) and VSV-Gpp entry in a dose-depen-
dent manner, which signifies the hindrance with a
process entailed for the HCVpp entry [71]. Fluphena-
zine, PCperazine, and trifluoperazine were currently
recognized as inhibitors of HCV entry [64]. These com-
pounds alienated the D2 and D1 dopamine [65,66] and
5-HT2 serotonin receptors [67] in neural signaling
networks.
A series of iridoids from Lamium album have been
appraised for their efficiency in blocking HCV cell entry
and HCVpp infection. The occurrence of the anti-HCV
iridoid aglycone epimers, lamiridosins A/B (1/2), in the
primed aqueous extract of Lamium album, have shown
the diminution in HCVpp entry due to interruption in
the binding of HCV E2 with CD81 receptor [68]. (Struc-
tures are cited in figure 4).
Conclusion
More importantly, it is crucial to appraise in-vitro
combinational therapy of small inhibitory molecules
with standard regime to improve antiviral activity
against HCV replication and infection. Therapeutic
drugs against HCV may have the potential to put off
the replication complex formation [37], to inhibit host
cell kinases [69], to block protein folding pathways
[70] and targeting to hormone receptors [71]. Accord-
ingly, therapeutic regime for HCV have been insinuat-
ing in a novel trail with less side effects and more
efficacy than standard therapy. Consequently, com-
pounds that may change any mechanism of cell regula-
tion which is provoked by HCV can have the
propensity to alleviate the infection. Various inhibitors
are now crossing the threshold in human clinical trials
in different phases such as BILN 2061, ITMN 191,
TMC 435350, MK 7009 (I & II phase) and a-ketoa-
mide (phase III) etc. For drug designing, main empha-
sis is made on three major targets but NS3 protease
inhibitors are the most successful one. But unfortu-
nately various drugs exhibit propensity to resistance
emergence. In order to avoid such problem, there is a
need to develop other potential antiviral drugs. So,
natural products should be included especially in com-
binational therapy which may prove to be a better
treatment option than standard therapy.
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Acridone derivatives 
 
      
Bromo-substituted derivative 
                                     (BIP)2B                                               
 
 
 
 
 
 
 
 
 
 
 
                       Tropolone derivatives                                                                     QU-663                         
 
 
 
 
 
TBBT                                               DRBT 
 
 
N O
NH
NH
O
N
N
Figure 3 Inhibitors of HCV helicase.
Rehman et al. Genetic Vaccines and Therapy 2011, 9:11
http://www.gvt-journal.com/content/9/1/11
Page 7 of 10 
                              P404,182                                                     Fluphenazine 
 
 
 
 
 
                     Trifluoperazine                              PCperazine                                                       
 
 
 
 
1,5,6,7-Tetrahydroxy-7-methyl-1,4a,5,6,7,7a-hexahydro-cyclopenta[c] pyran-4-
carboxylic acid methyl ester 
Figure 4 Inhibitors of HCV entry.
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